The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants, with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to ensuring that TMIST trial results will be applicable across races, ethnicities, and under-served communities.
FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.
